Decision: Favourable

Decisions Table

Study Title:

A Phase II, Double-blind, Placebo-controlled, Randomized, Dose-ranging, Parallel Group Study to Evaluate the Safety and Efficacy of PHA-022121 Administered Orally for Prophylaxis Against Angioedema Attacks in Patients with Hereditary Angioedema due to C1-Inhibitor Deficiency (Type I or Type II)

  • NREC Code:

    23-NREC-CT-020

  • Decision:

    Favourable

  • Meeting Date:

    24/03/2023

  • Study Type:

    CT application

  • Principal Investigator:

    Dr Niall Patrick Conlon

  • PI Institution:

    St. James's Hospital, Dublin

  • Sponsor:

    Pharvaris Netherlands B.V.

Scroll to Top